New York-Presbyterian Hospital

After three years of work, the EXaCT-1 exome cancer test has become part of clinical cancer care at NewYork-Presbyterian, but developers have higher ambitions.

The company hopes to raise funding this summer and has been conducting pilots with NewYork-Presbyterian Hospital and Memorial Sloan Kettering Cancer Center.

The partners aim to identify master regulators in the molecular networks of GIST patients that can serve as drug targets for existing treatments.

The test, EXaCT-1, may not only help doctors find treatments for patients who have run out of options but may also provide biomarkers of immunotherapy response.

The Irving Institute, a CUMC partnership with New York-Presbyterian, will fund its precision medicine program and the development of new therapies.

NEW YORK (GenomeWeb News) – Weill Cornell Medical College and New York-Presbyterian Hospital have partnered to launch a new institute that will pursue genome-centered translational medicine to deliver personalized care.

In the May issue of Cancer Prevention Research, Steven Lipkin and colleagues reported that in colon cancer cell lines, the protective effect against colorectal cancer was stronger in cells with a particular SNP in the HMGCR gene.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.